Background: Antibiotic resistance is a global health threat, especially with pathogens like Pseudomonas aeruginosa, which displays high resistance to many antibiotics. Innovative solutions, such as antimicrobial peptides (AMPs), are being explored to combat these multidrug-resistant organisms. The aim of the study:This study aimed to design and synthesize an antimicrobial peptide (AMP) effective against both antibiotic-resistant and susceptible strains of P. aeruginosa, while ensuring safety for human cells. Materials and methods: A novel antimicrobial peptide, WW-185, was designed based on the structure-function relationship of existing AMPs. Its antimicrobial activity was evaluated through Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) assays against standard and multidrug-resistant P. aeruginosa strains. Hemolytic activity was tested to assess safety for human erythrocytes, and time-kill assays were performed to study the peptide’s bactericidal action. Results: WW-185 demonstrated potent antimicrobial activity, with MIC and MBC values comparable to conventional antibiotics. It showed low hemolytic effects on human erythrocytes and exhibited rapid bactericidal action, killing bacteria within 15 minutes and maintaining efficacy for up to 24 hours. The peptide’s activity was attributed to bacterial membrane disruption, facilitated by its structural features. Conclusion: WW-185 is a promising antimicrobial candidate, with potent efficacy against multidrug-resistant P. aeruginosa and low toxicity to human cells. Its potential to reduce rapid resistance development makes it a valuable option for treating antibiotic-resistant infections